Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
June 29 2023 - 1:30AM
Press Release: Vaccines R&D pipeline raises the bar in RSV,
influenza, meningitis, and pneumococcal disease
Vaccines Investor EventVaccines R&D pipeline
raises the bar in RSV, influenza, meningitis, and pneumococcal
disease
- Sanofi reaffirms ambition to
deliver >€10bn in annual vaccines sales by 2030, fueled by an
accelerated pace of innovation
- Intent to start at least 5
innovative Phase 3 vaccine programs by 2025
Paris, June
29, 2023. Today Sanofi is hosting a
Vaccines Investor Event dedicated to its pipeline with key members
of its leadership team. The event will highlight how Sanofi’s
strategy is supported by vaccines R&D. Since 2019, reinvesting
in key growth drivers and a renewed pipeline has positioned the
company well as it moves at speed on the second phase of its Play
to Win strategy.
Sustained growth in the vaccines business will
be driven by core franchises of influenza, meningitis, and
pediatric vaccines, with the addition of a best-in-class RSV
franchise that aims to protect infants, toddlers and older adults.
Sanofi has made strides in bolstering its vaccines R&D,
including the rapid development of a leading-edge mRNA platform,
coupled with a global footprint of industrial and commercial
expertise.Thomas Triomphe Executive Vice
President, Vaccines, Sanofi“Today, we’re pleased to showcase how
vaccines R&D is significantly contributing to the continued
growth of the company through the design, development, and delivery
of vaccines that address unmet needs. The pace of our innovation is
buoyed both by a sense of urgency to address existing public health
needs at multiple stages in life, and by our continued
transformation as a company that simply won’t accept ‘good
enough.”
In less than two years, Sanofi has delivered a
competitive mRNA platform with improved potency and thermostability
that performs with both viral and bacterial targets. Using a
powerful internal and external innovation ecosystem, Sanofi’s mRNA
Center of Excellence has accelerated the science of mRNA
technology, including improved lipid nanoparticles.
Jean-François ToussaintGlobal
Head of Vaccines R&D, Sanofi“With the addition of mRNA, we now
have the largest development toolbox in the industry. This allows
us to tackle public health challenges like RSV across multiple
stages of life, applying the right platform to the right age group.
Adding machine learning and antigen design means that our future
vaccines will raise the bar beyond today’s high standards. With a
clear focus on delivering only first- and best-in-class vaccines,
we’re wholly focused on innovative R&D and flawless
execution.”
New data from 12 assets in
Sanofi’s broad vaccines pipeline will be featured today:
- Latest data from across the
RSV development program, including Phase 3b
HARMONIE data for Beyfortus (nirsevimab),
specifically designed to protect all infants against RSV when
entering their first season; positive Phase 1/2 data from the
first RSV vaccine designed to protect
toddlers (SP0125); and positive Phase 1/2 results
from the RSV mRNA vaccine in older
adults (SP0256), which lays the foundation for clinical
investigation of a combination vaccine with up to three different
pathogens (for example, Respiratory Syncytial Virus, human
Metapneumovirus, Parainfluenza virus) for older adults.
- First data from the
mRNA Flu
Quadrivalent vaccine, and promising results of the
next-generation
neuraminidase-encoding
mRNA Flu vaccine,
supporting further development of this novel program.
- Latest data from the Phase 1/2
pediatric pneumococcal vaccine program (SP0202/
developed in collaboration with SK Biosciences), with positive
safety and immunogenicity of the first PCV21 vaccine, designed to
extend protection against disease with an innovative carrier that
breaks the glass ceiling of serotype compositions. Phase 3 start of
pediatric pneumococcal vaccine planned in H1 2024, with expected
submission for approval in 2027.
- Sanofi will share recent clinical
evidence reinforcing MenQuadfi’s best-in-class profile and unique
ready-to-use syringe in the fight against
meningitis. FDA submission of MenQuadfi first and
only ready-to-use syringe scheduled for July 2023, with expected
launch in 2024. In addition, positive Phase 1/2 results from the
Men B program (SP0230) will be presented,
supporting a move to the next phase of development.
- In the realm of new frontiers,
Sanofi will introduce initial data from its multi-antigen
chlamydia
vaccine candidate, which will move to Phase 1/2 in early 2024; and
preclinical results with its therapeutic
mRNA vaccine candidate against
acne, which moves into Phase 1/2 in H2, 2023.
Vaccines Investor Event details Webcast and
presentation will be accessible here.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.comSally
Bain | + 1 617 834 6026
| sally.bain@sanofi.comEvan Berland | +1 215
432 0234 | evan.berland@sanofi.comVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.comArnaud
Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comTarik Elgoutni| + 1 617
710 3587 | tarik.elgoutni@sanofi.comNathalie
Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that pandemics or other
global crises may have on us, our customers, suppliers, vendors,
and other business partners, and the financial condition of any one
of them, as well as on our employees and on the global economy as a
whole. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31,
2022. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements.
Sanofi (EU:SAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Jul 2023 to Jul 2024